Hrow.O
Harrow Inc. operates in the Health Care sector, specifically within the Pharmaceuticals industry, generating revenue through its disclosed business activities.
Business. Harrow Inc. operates in the Health Care sector, specifically within the Pharmaceuticals industry, generating revenue through its disclosed business activities.
Analyst recommendations
8 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Harrow Inc. operates in the Health Care sector, specifically within the Pharmaceuticals industry, generating revenue through its disclosed business activities.
Harrow Inc. maintains a capital structure characterized by high leverage, with long-term debt of $250.0 million against total equity of $52.4 million, resulting in a debt-to-equity ratio of 4.77. The company holds $72.9 million in cash and equivalents, leading to a negative net cash position after subtracting total debt. Liquidity is assessed as medium risk, supported by a current ratio that is not explicitly provided but implied by the balance sheet composition. The market capitalization stands at $1.46 billion, reflecting a price-to-book ratio of 28.01 and an EV/Revenue multiple of 6.09.
Profitability metrics indicate operational challenges, with a net income of -$5.1 million and an operating income of $30.5 million on revenues of $272.3 million. The return on equity is -28.53%, and the return on assets is -3.75%, signaling negative returns on invested capital. Gross profit is $204.4 million, suggesting a gross margin of approximately 75%, which is typical for pharmaceutical companies, but operating expenses erode this advantage. Without cohort median data, direct comparison to industry peers is omitted, but the negative net income contrasts with the positive operating cash flow of $43.9 million.
Revenue concentration by segment or geography is not disclosed in the available data. The company’s total revenue of $272.3 million is attributed to its overall operations without further breakdown.
Growth trajectory analysis is limited due to the absence of historical period data. The current revenue figure of $272.3 million serves as the baseline for future projections.
Risk factors include medium liquidity risk and low dilution risk. The key flag notes that net cash is negative after subtracting total debt, highlighting leverage concerns. The high debt-to-equity ratio of 4.77 further underscores financial leverage risks.
Recent events include analyst estimates with a mean price target of $65.57 and a median price target of $60.00, indicating positive market sentiment. The mean recommendation is 1.62, with 3 strong buys and 5 buys, and no holds. News observations indicate reconciler enqueue events for analysis jobs, but no specific corporate actions or news events are detailed.
- High leverage with a debt-to-equity ratio of 4.77 and negative net cash position.
- Negative profitability with a net income of -$5.1 million and ROE of -28.53%.
- Strong analyst sentiment with a mean price target of $65.57 and 1.62 recommendation.
- Positive operating cash flow of $43.9 million despite net losses.
- Low dilution risk but medium liquidity risk.
- "margin_outlook_rationale": "Gross margins are strong at ~75%, but operating margins are pressured by high expenses, leading to net losses.",
Bull / Bear case
analysis pipelineIn focus — financials by report
Revenue $44.2M, −7,6% YoY; Operating income −96,6% YoY.
- ▍Revenue $44.2M, −7,6% YoY
- ▍Operating income −96,6% YoY
- ▍Net income −55,2% YoY
- ▍Free cash flow −203,3% YoY
- ▍Net margin -62.4%
Revenue $89.1M, +33,3% YoY; Operating income +20,9% YoY.
- ▍Revenue $89.1M, +33,3% YoY
- ▍Operating income +20,9% YoY
- ▍Net income −2,2% YoY
- ▍Free cash flow +142,0% YoY
- ▍Net margin 7.4%
Revenue $71.6M, +45,4% YoY; Operating income +429,7% YoY.
- ▍Revenue $71.6M, +45,4% YoY
- ▍Operating income +429,7% YoY
- ▍Net income +124,2% YoY
- ▍Free cash flow +411,4% YoY
- ▍Net margin 1.4%
Revenue $63.7M, +30,2% YoY; Operating income +645,7% YoY.
- ▍Revenue $63.7M, +30,2% YoY
- ▍Operating income +645,7% YoY
- ▍Net income +177,2% YoY
- ▍Free cash flow +350,4% YoY
- ▍Net margin 7.8%
Revenue $47.8M; Operating income -$11.2M.
- ▍Revenue $47.8M
- ▍Operating income -$11.2M
- ▍Net margin -37.2%
Revenue $66.8M; Operating income $12.9M.
- ▍Revenue $66.8M
- ▍Operating income $12.9M
- ▍Net margin 10.1%
Revenue $49.3M; Operating income $1.3M.
- ▍Revenue $49.3M
- ▍Operating income $1.3M
- ▍Net margin -8.6%
Revenue $48.9M; Operating income $1.5M.
- ▍Revenue $48.9M
- ▍Operating income $1.5M
- ▍Net margin -13.2%
Revenue $272.3M, +36,4% YoY; Operating income +158,1% YoY.
- ▍Revenue $272.3M, +36,4% YoY
- ▍Operating income +158,1% YoY
- ▍Net income +70,6% YoY
- ▍Free cash flow +129,8% YoY
- ▍Net margin -1.9%
Revenue $199.6M, +53,3% YoY; Operating income +275,2% YoY.
- ▍Revenue $199.6M, +53,3% YoY
- ▍Operating income +275,2% YoY
- ▍Net income +28,4% YoY
- ▍Free cash flow +74,3% YoY
- ▍Net margin -8.8%
Revenue $130.2M, +47,0% YoY; Operating income −362,3% YoY.
- ▍Revenue $130.2M, +47,0% YoY
- ▍Operating income −362,3% YoY
- ▍Net income −73,3% YoY
- ▍Free cash flow −1 113,2% YoY
- ▍Net margin -18.7%
Revenue $88.6M, +22,2% YoY; Operating income −28,3% YoY.
- ▍Revenue $88.6M, +22,2% YoY
- ▍Operating income −28,3% YoY
- ▍Net income +21,8% YoY
- ▍Free cash flow +26,4% YoY
- ▍Net margin -15.9%
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,23 |
| Revenue | —no estimate | —no estimate | 348,5M USD |
| Operating income | —no estimate | —no estimate | 38,9M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Director · RSU → Common StockAcquired 5 248grant · 2026-06-18
- Director · RSU → Common StockAcquired 5 248grant · 2026-06-18
- Director · RSU → Common StockAcquired 5 248grant · 2026-06-18
- CHIEF SCIENTIFIC OFFICER · Restricted Stock Units → Common StockAcquired 10 000grant · 2026-05-15
- CHIEF COMMERCIAL OFFICER · RSU → Common StockAcquired 15 000grant · 2026-01-30
- CHIEF COMMERCIAL OFFICER · RSU → Common StockAcquired 25 000grant · 2026-01-30
- Director, CHIEF EXECUTIVE OFFICER · Stock Option (Right to Buy) → Common StockDisposed 180 000 @ $3,95exercise · 2025-12-12
- PRESIDENT AND CFO · Stock Option (Right to Buy) → Common StockDisposed 60 000 @ $3,95exercise · 2025-12-12
- CHIEF ACCOUNTING OFFICER · Stock Option (Right to Buy) → Common StockAcquired 30 000 @ $39,00grant · 2025-09-01
Actions
Ask Handelsavisen
- Reference data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Cash Conversion Ratiooperating_cash_flow / net_income
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Market Capmarket_price * shares_outstanding_diluted
- Harrow, Inc. Market data — financials · 2026-07-29
- reconciler_enqueue (reconciler) on HROW.O · 2026-07-29
- Harrow Inc Market data — analyst estimates · 2026-07-29
- Harrow Inc Market data — ESG · 2026-07-29
- HROW.O HA canonical relationships · 2026-07-29
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$20M
- Investment Managers · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$30M
- Investment Managers · as of 2026-03-310,00 %$12M
- Investment Managers · as of 2026-03-310,00 %$10M
- Investment Managers · as of 2026-03-310,00 %$10M
- Investment Managers · as of 2025-12-310,00 %$94M
- Investment Managers · as of 2026-03-310,00 %$6M
- Investment Managers · as of 2024-12-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$30M
- Investment Managers · as of 2024-06-300,00 %$45M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$3M
- Institutional Investor · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Funds · as of 2026-03-310,00 %$1M
- Brokerage Firms · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- Mark L. BaumChairman of the Board, Chief Executive Officer
Insider activity
- Director · Common StockBought 1 000 @ $31,07$31K · 2026-05-18
- Director · Common StockBought 1 000 @ $31,00$31K · 2026-05-18
- Director, CHIEF EXECUTIVE OFFICER · Common StockBought 10 000 @ $30,20$302K · 2026-05-14
- PRESIDENT AND CFO · Common StockBought 3 500 @ $29,90$105K · 2026-05-14
- 10% owner · Common Stock, par value $0.001 per shareSold 134 000 @ $39,67$5,3M · 2026-03-04
- 10% owner · Common Stock, par value $0.001 per shareSold 4 263 @ $39,67$169K · 2026-03-04
- 10% owner · Common Stock, par value $0.001 per shareSold 1 309 @ $39,15$51K · 2026-03-03
- 10% owner · Common Stock, par value $0.001 per shareSold 59 000 @ $39,15$2,3M · 2026-03-03
- 10% owner · Common Stock, par value $0.001 per shareSold 5 000 @ $54,18$271K · 2026-02-27
- 10% owner · Common Stock, par value $0.001 per shareSold 20 000 @ $53,35$1,1M · 2026-01-06
- PRESIDENT AND CFO · Common StockOther 60 000 @ $3,95$237K · 2025-12-12
- Director, CHIEF EXECUTIVE OFFICER · Common StockOther 79 994 @ $47,06$3,8M · 2025-12-12
- Director, CHIEF EXECUTIVE OFFICER · Common StockOther 180 000 @ $3,95$711K · 2025-12-12
- PRESIDENT AND CFO · Common StockOther 26 665 @ $47,06$1,3M · 2025-12-12
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Total assets (annual): USD 399.48MUnknown
- Gross profit (annual): USD 204.37MUnknown
- Cost of revenue (annual): USD 67.93MUnknown
- Operating cash flow (annual): USD 43.86MUnknown
- Total operating expenses (annual): USD 173.85MUnknown
- Current assets (annual): USD 211.75MUnknown
- EPS (diluted) (annual): USD-PER-SHARES -0Unknown
- Current liabilities (annual): USD 96.3MUnknown
- Pre-tax income (annual): USD -1.37MUnknown
- Total liabilities (annual): USD 347.39MUnknown
- Shareholders' equity (annual): USD 52.45MUnknown
- Shares outstanding (annual): 37.23MUnknown
- Cash & equivalents (annual): USD 72.93MUnknown
- EPS (basic) (annual): USD-PER-SHARES -0Unknown
- R&D expense (annual): USD 20.94MUnknown
- Capex (annual): USD 887KUnknown
- Operating income (annual): USD 30.52MUnknown
- Revenue (annual): USD 272.3MUnknown
- Net income (annual): USD -5.14MUnknown
- Long-term debt (annual): USD 250MUnknown
- Shares outstanding (annual): 35.62MUnknown
- Current liabilities (annual): USD 91.34MUnknown
- Operating income (annual): USD 8.82MUnknown
- Total operating expenses (annual): USD 141.55MUnknown